Our latest articles
2021 rounds off with key FDA decisions for Argenx, Calliditas and Merck, while Novartis will be hoping for an early Leqvio verdict.
Look out Amryt: Krystal’s topical gene therapy is gaining ground.
Amid cautionary tales of other highly valued unpartnered assets, efgartigimod approaches its US date with destiny.
Efficacy of Merck/Ridgeback’s molnupiravir shows an alarming fall-off, just as a US regulatory panel review beckons.
Roche, its coffers full from coronavirus test sales, ups its research spending – but Baxter cuts back.
Could Gilead soon be looking for a new partner for its long-acting project lenacapavir?
The sellside expects the world’s leading medtech to be outpaced by its rivals. Divestments might allow the group to defy this destiny.
The group’s deal with Sosei will see it compete with Karuna and Cerevel.
Diagnostics companies enjoy notable uplift in sales; elsewhere, spinouts could shape the future.
After a frothy couple of years, biotechs are no longer seeing big boosts from clinical data.